#JPM22: Catal­ent CEO John Chimin­s­ki with John Car­roll — Our pre­dic­tions for the bio­phar­ma in­dus­try in 2022

Dur­ing our JPM22 week of events, I had a chance to sit down with Catal­ent CEO John Chimin­s­ki for our an­nu­al fore­cast for the year ahead. It’s al­ways a lot of fun, and Chimin­s­ki had a chance to talk about the big tran­si­tion ahead for his com­pa­ny, CD­MOs, and what looks like a very event­ful 12 months for bio­phar­ma. — John Car­roll

John Car­roll:

Okay! Well. Hey, every­body. This is John Car­roll, I’m the ed­i­tor of End­points News. And I am very hap­py to in­tro­duce John Chimin­s­ki back again, CEO of Catal­ent. And John is join­ing me once again to be talk­ing about what’s go­ing on next year, what’s hap­pen­ing. We’ve done this be­fore. Gen­er­al­ly, it’s al­ways good to have you be here, John. But one thing that we can say that’s ab­solute­ly cer­tain that’s go­ing to hap­pen in 2022 is there’s go­ing to be a tran­si­tion at Catal­ent. And I want­ed to talk a lit­tle bit about that.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER